We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 52 for:    "Central serous chorioretinopathy"

Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01019668
First Posted: November 25, 2009
Last Update Posted: July 25, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Shin Kong Wu Ho-Su Memorial Hospital
  Purpose
The purpose of this study is to evaluate the effectiveness as well as the detrimental influence of half-dose and half-fluence modification of verteporfin photodynamic therapy (PDT) for the treatment of prolonged unresolved central serous chorioretinopathy (CSCR).

Condition Intervention
Central Serous Chorioretinopathy Drug: Verteporfin PDT, half-dose Drug: verteporfin PDT, half-fluence

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy

Resource links provided by NLM:


Further study details as provided by Shin Kong Wu Ho-Su Memorial Hospital:

Primary Outcome Measures:
  • Effectiveness of both modification for the treatment of chronic CSCR Fluorescent leakage as regards to BCVA OCT changes [ Time Frame: within 6 months ]

Secondary Outcome Measures:
  • Detrimental influence on choroidal perfusion Represented by the decrease of fluorescent intensity In ICGA [ Time Frame: within 6 months ]

Enrollment: 24
Study Start Date: November 2008
Study Completion Date: June 2011
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: verteporfin PDT, half-dose
use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
Drug: Verteporfin PDT, half-dose
half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
Other Name: visudyne
Drug: verteporfin PDT, half-fluence
half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
Other Name: visudyne
Active Comparator: verteporfin PDT, half-fluence
use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
Drug: Verteporfin PDT, half-dose
half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
Other Name: visudyne
Drug: verteporfin PDT, half-fluence
half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
Other Name: visudyne

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with best-corrected visual acuity (BCVA) of 20/200 or better
  • Presence of subretinal fluid (SRF) and/or serous pigment epithelial detachment (PED) involving the fovea on optical coherence tomography (OCT)
  • Presence of active angiographic leakage in fluorescein angiography (FA) caused by CSC but not CNV or other diseases
  • Abnormal dilated choroidal vasculature and other features in ICGA consistent with the diagnosis of CSC.

Exclusion Criteria:

  • Patients who received previous PDT or focal thermal laser photocoagulation for the treatment of CSC.
  • Patients had evidence of CNV, polypoidal choroidal vasculopathy, or other maculopathy on clinical examination, FA, or ICGA
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01019668


Locations
Taiwan
Shin Kong Wu Ho-Su Memorial Hospital
Taipei, Taiwan, 111
Sponsors and Collaborators
Shin Kong Wu Ho-Su Memorial Hospital
Investigators
Principal Investigator: Cheng-Kuo Cheng, MD Shin-Kong Wu Ho-Su Memorial Hospital, School of Medicine, Fu-Jen Catholic University
  More Information

Responsible Party: Cheng-Kuo Cheng, Assistant professor and attending physician of Ophthalmology, Shin-Kong Wu Ho-Su Memorial Hospital, School of Medicine, Fu-Jen Catholic University
ClinicalTrials.gov Identifier: NCT01019668     History of Changes
Other Study ID Numbers: SKH-8302-98-DR-27
First Submitted: November 19, 2009
First Posted: November 25, 2009
Last Update Posted: July 25, 2011
Last Verified: July 2011

Keywords provided by Shin Kong Wu Ho-Su Memorial Hospital:
chorioretinopathy
photodynamic therapy
reduced fluence
reduced dose

Additional relevant MeSH terms:
Central Serous Chorioretinopathy
Retinal Diseases
Eye Diseases
Verteporfin
Photosensitizing Agents
Dermatologic Agents